hematologic and oncologic emergencies

advertisement

hematologic and oncologic emergencies wes miller fellow, pediatric hematology and oncology october 31 2007

objectives: AMBITIOUS!

• review common presentation, pathophysiogy and (emergent) management of the following

– the bleeding hemophiliac

– “the bleeding patient with immune thrombocytopenia purpura (ITP)”

– tumor lysis syndrome in the patient with a new malignancy

– hyperleukocytosis in acute leukemias or myeloproliferative disease (MPD)

– typhlitis

– superior vena cava syndrome in the patient with a mediastinal mass

the sickler...

• presents a whole new set of emergencies

– potential for great morbidity and mortality

• more familiar to most ED docs in Atlanta

• not addressed here

but, first...

• THANKS

for the job you do for out patients

• we realize our patients are

HIGH

MAINTENANCE

• our attitude on the phone is often one of

caution

– at risk population

– subtleties matter

the bleeding hemophiliac

• 8 month old male

• presented to PMD with 1 week hx of progressive bilateral LE weakness

– diagnosed with GBS, sent to SR ED

• at SR ED, noted to have multiple bruises over body ( not just over shins ), many nodular and hard

• history of sublingual frenular bleed x 10 days following mild trauma in past

• history of 2 weeks of oozing at surgical site following neonatal circumcision

• history of LP at 6 weeks of life for fever (RSV)

– waxing and waning “bulging bruise” at site EVER

SINCE

the bleeding hemophiliac

• family history negative for bleeding disorders

• child with history of vit K ppx at birth, no warfarin or rat poison exposures, no recent antibiotics or diarrhea.

• Formula fed; typical baby foods

• PE: alert, smiling, clapping. VS wnl. no spontaneous movement of BLE, no withdrawal from painful stimuli, patellar areflexia

• CBC normal, platelets robust

• PT: 12.6 seconds (normal)

• PTT: 125.6 seconds (not normal)

• ultrasound: massive thoracolumbosacral paraspinal hematoma

the bleeding hemophiliac

the bleeding hemophiliac

• normally, the known hemophiliac will present to your ED

• hemophilia

– A (“classic”): factor 8 deficiency

– B (“christmas disease”): factor 9 deficiency

– both coded on X chromosome

– disease due to absent or dysfunctional protein

– clinically INDISTINGUISHABLE

– prevalence: 1 in 7500 males

– hemophilia A seven times more common than hemophilia B

the bleeding hemophiliac

• hemophilia graded according to degree of factor dysfunctionality:

– severe: <1% native activity

– moderate: 1% - 5% native activity

– mild: >5% native activity

• where do hemophiliacs bleed?

– everywhere!!!

– mucocutaneous bleeds (epistaxes, oral, GI)

– SOFT TISSUE BLEEDS

• HEMARTHROSES!!!!!

• muscle bleeds (ileopsoas!)

• eyes, renal/GU, throat

• CNS !!!!!!!

the bleeding hemophiliac

• treatment options

– respective recombinant factor replacement

(both F8 and F9 deficiency)

– DDAVP (mild factor 8 deficiency)

– FFP **** (factor 9 deficiency)

– cryoprecipitate **** (factor 8 deficiency)

– antifibrinolytics (amicar)

• treatment strategies

– “on demand”

– primary prophylaxis

– secondary prophylaxis

the bleeding hemophiliac

• DOSING SPECIFICS

– recombinant factor 8 dosing:

• 1 unit/kg of factor 8 raises the activity level 2%

– recombinant factor 9 dosing:

• 1.5 unit/kg of r-factor 9 raises the acvity level 1%

• beware anaphylaxis in F9 replacement

• FUNDAMENTAL PRINCIPLE:

– when in doubt, treat!!!!

• standard rule of thumb:

– correct the bleeding hemophiliac child to 80%

- 100% activity

the bleeding hemophiliac

• barriers to therapy: the dreaded factor inhibitor

– 25% - 30% in F8 deficiency

– 3% in F9 deficiency

• options for patients with inhibitors

– FEIBA

• do not use antifibrinolytics with FEIBA

– recombinant VIIa (novoseven)

– antifibrinolytics (amicar)

ITP

• 3 y/o male presents with sudden onset , 1 day history full body petechiae and purpura

• no epistaxis, melena, hematochezia, hematuria, no h/a, no emesis

• no recent fever, no bony pains; excellent energy and appetite

• no chronic medications, but mom gave robitussin 2 weeks ago for “cold”

• mom frantic: just saw FoxNews special and wants to know if child dying of “meningitis”

ITP

• PE: vs wnl

• child jumping up and down on exam bed

• 8 year old brother then tackles patient who is giggling and about to fall off the bed

• head to toe petechia and purpura

• OC with multiple purpura, none oozing

• CN exam normal, neuro exam normal

• no HSM

• CBC with differential:

– WBC 6k/microL, relative lymphocytosis, 10% atypical lymphocytes, ANC 2000

– hgb 11.8 g/dL

– platelets <10k/microL

ITP

• the most common AI disorder affecting a hematologic element (1:10,000 kids/year)

• peak age: 2 - 6 years

• males = females (children)

• 2 flavors:

– acute (spontaneous resolution < 6 months)

– chronic (persistance > 6 months)

ITP

• cause: macrophagic destruction of antibody-sensitized platelets

– occurs in RES

– primary site: spleen

• clinical course

– usually, antecedent viral illness/vaccination in weeks prior to onset

– abrupt onset bleeding/bruising

– otherwise HEALTHY kid

ITP

• how low do they go??

– plts < 20K: over 80%

– usually isolated : expect normal WBC, hgb

• anemia in 15% of cases: extracorporeal losses

• splenomegaly?

– palpable spleen present in 10%

• peripheral smear “mandatory”

– confirm true t’penia (rule out spurious!)

– may see large plts

– important negatives:

• no WBC abnormalities

• no evidence of MAHA

• no evidence of AIHA

• other work-up:

– direct antibody test (DAT/direct Coomb’s)

– ABO/Rh blood type

treatment

ITP

intracranial hemorrhage risk

ITP

• where, exactly, do ITP kiddos bleed??

– “most” with petechiae/ecchymoses/purpura

– epistaxis/oral wet purpura in < 30%

– GI (melena/hematochezia), hematuria in < 10%

– menorrhagia in appropriate age group

ICH: 0.1% - 0.9%

• how prone to serious bleeding are ITP patients??

– not very!!!

– concept of total body platelet mass

– bone marrow: LOTS of megakaryocytes!

– compare to other thrombocytopenic contexts

• iatrogenic post chemo!

– risk stratification with absolute platelet count

• < 20K/microL: greatest

• 20K - 50K/microL: moderate

• >50K : insignificant

ITP

• reasons to treat:

– suspected ICH

– known ITP with significant trauma

– recurrent or unabating mucosal bleeding

– anemia secondary to loss

– rarely: extenuating social situation

NOT

reasons to treat:

– parental anxiety

– petechiae or purpura, no matter how florid

ITP

• management armamentarium

1. educate, educate, educate

2. anticipatory guidance

3. counsel to avoid antiplatelet meds (ASA, NSAIDs)

4. Platelets are NOT TYPICALLY HELPFUL****

5. observation is commonest strategy

6. WinRho : monoclonal anti-Rho D antigen antibody

1.

only for non-anemic, DAT negative, Rh+ patients

7. IVIG

8. steroids*****

9. other immunomodulatory agents

10. splenectomy

ITP

• to marrow or not to marrow ???

– good concensus: do not marrow if

• clinical gestalt consistent with ITP

• plan observation alone

• plan IVIG and/or anti-D therapy

– debatable

• plan corticosteroid treatment (even in kids with clinical constellation classic for ITP)

– good concensus: marrow if atypical clinical picture

• natural history:

– resolution in 50% by 4 - 8 weeks

– resolution in 65% by 3 months

– resolution in 75% by 6 months

– 1/3 of “chronic” patients will spontaneously resolve

– factors associated with chronicity:

• females

• age older than 10 (also very young?)

• insidious onset

tumor lysis syndrome (TLS)

• 8 year old male presents with rapidly distending abdomen , first noticed 4 days ago

• febrile, anorexic, pale; stooled yesterday; decreasing UOP

• PE: mild distress, large palpable discreet mass in right lower abdomen

• CT: large mass near ileocecum

• CBC:

– WBC 10 K/microL

– 3% blasts

– mild anemia.

• chemistries:

– LDH 22,000 U/L (quite high)

– uric acid: 12 mg/dL (quite high)

– K: 6.1 mmol/L (elevated)

– creatinine: 1.3 mg/dL (elevated)

– phos: 9 mg/dL (elevated)

TLS

high [K+] purines high [phos]

TLS

• sudden burden of intravascaular potassium, phosphate and uric acid spilled by dying tumor cells

– rhabdomyolysis

– crush injuries

– thermal injuries (burns/hypothermic exposure)

• secondary to massive synchronous release of intracellular contents into extracellular space

• typically seen at initiation of therapy for new malignancy, but MAY BE SEEN AT PRESENTATION

• consequences:

– acute renal failure (urate and CaPhos crystal tubulopathy)

– cardiac dysrhythmias

– acute hypocalcemia

TLS

• identifying patients at risk:

– lymphomas :

• classically, Burkitt’s lymphoma (practically, any NHL with short doubling time and bulky disease)

– leukemias :

• especially with high peripheral WBC (>100k/microL)

• especially with large extramedullary disease burden : massive HSM, bulky T cell leukemia/lymphoblastic lymphoma

• especially with nephromegaly : suggests leukemic renal parenchymal involvement

– lymphoproliferative disorders

• CML, JMML

TLS

• interventions:

– hyper-hydration :

• beware of oliguria

• 2-3 x maintenance of NON POTASSIUM CONTAINING IVF

• ?alkalanization

– NOT AT CHOA

– kayexelate (ideally, oral only), concomitant insulin and glucose, albuterol, CaGluconate****

– renagel

– be CAUTIOUS: give supplemental calcium only with

EKG changes with hyperkalemia or symptomatic hypocalcemia

• goal: keep calcium-phosphate product LOW (<60)

TLS

• interventions:

– allopurinol

• inhibits hypoxanthine oxidase

• enzyme critical in metabolic pathway from purine → →

→uric acid

– rasburicase

• urate oxidase

• converts uric acid to soluble metabolite (allantoin)

• $$$$$

• consult with heme/onc before giving

– begin treating malignancy !!!!

hyperleukocytosis

• 7 year old male presents to SR ED with CC of decreased energy x 7 days, unresponsive today

• exam:

– combative, confused, averbal

– pupils anisocoric, but responsive

– hemiparesis

– pallor

– tachycardic with gallop

– massive HSM

• CBC:

– WBC: 327K/microL, 94% blasts

– hgb: 4.6 g/dL

– plts: 16K/microL

• DIC panel:

– PT: 24 seconds (prolonged)

– PTT: 28 seconds (normal)

– firbrinogen: 60 (low)

– DDimers: 4100 (elevated)

hyperleukocytosis

hyperleukocytosis

• patient intubated

• surgery emergently consulted to place vas-cath

• patient leukapheresed x multiple cycles in PICU

• flow cytometry: acute T-cell lymphoblastic leukemia

• progressed to renal failure, CVVH

• worsening neurologic picture, unilateral fixed pupil

• neurosurgery: cranial flap

hyperleukocytosis

hyperleukocytosis

• presence of excessive blastemia in the leukemic

• defined by peripheral WBC of at least

100K/microL

• risk of symptomatology greatly increased for counts of 300K/microL or more

• risk of symptomatology greatly increased in AML and CML with increased circulating myeloblasts

• seen in

– AML: 5%- 20% at presentation

– ALL: 9% - 13% at presentation

– CML: nearly all patients at presentation

hyperleukocytosis

• pathophysiology:

– supraphysiologic whole blood viscosity :

LEUKOSTASIS

– aggregation of blasts in microvasculature

• rheologic properties of MYELOBLASTS contribute to worse outcomes in AML or CML

– larger than lymphoblasts

– less distensible than lymphoblasts

– “stickier” than lymphoblasts

hyperleukocytosis

• Pathophysiology

– inappropriate activation of soluble phase clotting cascade

– microvascular occlusion

• distal ischemic injury/metabolic acidosis

• MAHA (on top of myelophthistic cytopenias)

• DIC

• reperfusion hemorrhage

– MSOF (CNS, pulmonary, renal, hepatic, cardiac, dactylitis, priapism, etc.

)

hyperleukocytosis

• Interventions   DECREASE WHOLE

BLOOD VISCOSITY :

– primary intervention: CYTOREDUCTION

• leukapheresis

• cytoreductive chemotherapy

– immediately notify heme/onc

• we will urgently activate ARC cytapheresis folks

– in the meantime, tip balance to LESS viscosity

• immediately begin hyper-hydration (2-3 x maintenance) with non-K+ containing IVF

• AVOID PRBC transfusions !

– markedly increase whole blood viscosity

– if necessary, transfuse with ceiling hgb of 8-9 g/dL

• may transfuse platelets liberally if necessary

hyperleukocytosis

• interventions:

– correct coagulopathy ???

• depends!

– make plans for urgent placement of vas-cath

– manage TLS

• who gets leukapheresed ?

– ANY PATIENT WHO IS SYMPTOMATIC FROM

SUSPECTED LEUKOSTASIS SYNDROME

– asymptomatic patients:

• suspected AML : WBC > 100K/microL

• suspected ALL: WBC > 200K/microL

• suspected CML: WBC > 200K/microL

typhlitis

• 4 year old female

• fever to 103, abdominal pain, emesis, bloody diarrhea x one day

• undergoing induction chemotherapy for standard risk, Bprecursor ALL

– finished 2 week steroid course 3 days go

• exam:

– toxic appearing

– tachycardic and hypotensive

– mild abdominal distension, hypoactive bowel sounds

– guarding on abdominal exam with marked TTP in RLQ

– Central capillary refill > 5 seconds

• KUB and cross-table lateral: no free air, possible pneumatosis intestinalis noted

• CT abdomen: marked cecal bowel wall thickening , peumoatosis intestinalis present

typhlitis

• inflammation of the bowel wall, especially at the level of the cecum

• seen in children with PROLONGED and

PROFOUND neutropenia

• Increased risk following chemotherapeutic drugs which cause mucositis

• pathogenesis is essentially parallel to neonatal

NEC (nectrotizing enterocolitis)

– transmural bacterial translocation: PI

– risk of bowel perforation

– risk of translocated bacteremia: SIRS

• pseudomonas aeruginosa

• clostridium septicum

typhlitis

• at risk patients:

– leukemics or NHL patients in induction

• may be seen in consolidation for higher intensity regimens

– following systemic cytarabine (ARA-C) therapy

• especially post high dose cytarabine

– any patient with prolonged, profound neutropenia

– beware the child “in leukemic induction, coming off steroids, with sudden fever and acute abdomen/signficant RLQ pain”

typhlitis

• interventions:

– fluid resuscitation

– blood culture; stool culture if available

– avoid rectal exam

– empiric broad spectrum antibiotics (GP, GN, anaerobic coverage)

• vancomycin, meropenem +/- aminoglycoside

– evaluate for perforation (KUB/CT)

• surgery consult if present

– inotropic support for hypotension unresponsive to fluid resuscitation

superior vena cava syndrome

• 12 year old male, previously healthy

• 6 week history of worsening cough

– treated 1 week into symptoms with 2 weeks of systemic steroids for “bronchitis”

– initially cough improved and felt much better

– now worsening

– 20 pound weight loss

• past week:

– worsening orthopnea (sleeping upright in chair)

– fevers

• past 2 days:

– expanding mass in supraclavicular area

SVCS

• exam:

– alert and non-toxic; completely oriented

– facial edema

– no stridor, not dyspneic

– tachypneic, absent breath sounds R lung

– palpable, firm nodes in right supraclavicular chain

– splenomegaly

SVCS

SVCS

SVCS

• CBC:

– WBC: 12K/microL, 13% blasts

– hgb: 11.9 g/dL

– plts: 144K/microL

• quantitative βhCG (tumor marker): normal

• quantitative AFP (tumor marker): normal

• stat peripheral flow: T cell acute lymphoblastic lymphoma (leukemia?)

SVCS

• Interventions:

– ICU observation

– begun on empiric high dose solumedrol

• based upon presence of blasts in smear

– next day, begun on induction chemotherapy per flow cytometric diagnosis

SVCS

• signs and symptoms from impedence to flow in the SVC

– plethora

– facial edema

– JVD

– dyspnea

– orthopnea

– cough

– stridor

• for advanced SVC obstruction, may see

– confusion

– lethargy

– headache

– vision changes

• usually, abnormal SVC flow results from extravascular compression, not a primary intraluminal thrombus

SVCS

• causes: mediastinal badness

– malignancy

• NHL (70% of malignant causes of SVCS)

• HL

• neuroblastoma

• leukemias***

• germ cell tumors

– granulomatous disease

– aortic aneurysms

– primary SVC thrombus

SVCS

• accurate diagnosis is critical...

• ...however, tissue acquisition can be problematic

– do NOT sedate

– do NOT give anxiolytics

– avoid anything which will compromise

• muscular tone

• venous return

• an already taxed cardiopulmonary state

SVCS

• workup:

– CXR, CT to evaluate mass location, size, airway patency, encasement of vessels, presence of pleural effusion , etc.

– evidence of hematolymphoid malignancy?

• BLASTS on peripheral smear

• empirically send peripheral blood flow cytometry

• bone marrow aspirate and biopsy under local anesthesia

– meticulous lymphatic exam

• may reveal tissue source obtainable via local anesthetic only

– urine catecholamines (VMA/HVA) if clinical picture consistent with neuroblastoma

– serum QUANTITATIVE (tumor marker) βhCG and AFP for GCT

– transthoracic echocardiogram: presence of pericardial effusion

– PPD/ID titers

SVCS

• consult anaesthesia for symptomatic or unstable patient

• unstable for general anesthesia:

– >50% reduction in cross-sectional diameter of trachea at any level

– <50% predicted PEFR on PFT’s

SVCS

• interventions:

– ultimately, begin treatment for underlying cause

• however, may BE FACED WITH UNSTABLE

PATIENT and no diagnosis:

– awaiting pathologic analysis of obtained sample, or

– danger of obtaining any sample for tissue diagnosis

• initiate empiric therapy:

– solumedrol: 2 mg/kg/day divided tid

– external beam radiation

– if high clinical suspicion of GCT or NBL, initiate appropriate chemotherapy

Download